Table II.
Multivariate Cox regression analysis of the overall survival of patients with renal cell carcinoma.
| A, Training group (n=100) | ||
|---|---|---|
| Clinicopathological feature | P-value | HR (95% CI) |
| Age (≥60 vs. <60 years) | 0.120 | 1.532 (0.895–2.621) |
| Gender (male vs. female) | 0.267 | 0.734 (0.425–1.267) |
| T stage (T3-T4 vs. T1-T2) | 0.097 | 1.664 (0.911–3.040) |
| Lymph node (N3-N4 vs. N0-N2) | 0.092 | 1.601 (0.926–2.767) |
| Metastasis (positive vs. negative) | 0.368 | 1.399 (0.673–2.906) |
| TNM stage (III–IV vs. I–II) | 0.619 | 1.163 (0.641–2.112) |
| Grade (III+IV vs. I+II) | 0.064 | 1.6681 (0.970–2.913) |
| CD103expression (high vs. low) | 0.001 | 0.365 (0.205–0.648) |
| B, Testing group (n=100) | ||
| Clinicopathological feature | P-value | HR (95% CI) |
| Age (≥60 vs. <60 years) | 0.995 | 0.998 (0.535–1.861) |
| Gender (male vs. female) | 0.555 | 1.211 (0.641–2.288) |
| T stage (T3-T4 vs. T1-T2) | 0.946 | 1.000 (0.549–1.820) |
| Lymph node (N3-N4 vs. N0-N2) | 0.063 | 1.801 (0.968–3.349) |
| Metastasis (positive vs. negative) | 0.595 | 0.804 (0.360–1.795) |
| TNM stage (III–IV vs. I–II) | 0.776 | 0.910 (0.475–1.743) |
| Grade (III+IV vs. I+II) | 0.233 | 1.460 (0.784–2.718) |
| CD103 expression (high vs. low) | 0.003 | 0.391 (0.210–0.728) |
HR, hazard ratio; CI, confidence interval; TNM, tumor-node-metastasis; CD, cluster of differentiation.